MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Positron emission tomography(PET)"

  • 2016 International Congress

    Evaluation of the [ 99mTc] – TRODAT- 1 SPECT in the diagnosis of Parkinson’s disease and other movement disorders

    G. Fabiani, R. Martins Filho, H.A.G. Teive (Campina Grande do Sul, Brazil)

    Objective: Evaluation of the [ 99mTc] - TRODAT- 1 SPECT in the diagnosis of PD and other MD. Create a DATA bank for our population.…
  • 2016 International Congress

    PET examination of the monoamine transporter with 11C-beta-CIT

    M. Tábuas-Pereira, F. Oliveira, A. Moreira, M. Sousa, F. Moreira, C. Januário, A. Abrunhosa, M. Castelo-Branco (Coimbra, Portugal)

    Objective: To investigate the utility of 11C-β-CIT PET scan on Parkinson's disease diagnosis. Background: The monoamine reuptake sites transport dopamine, noradrenaline and serotonin from the…
  • 2016 International Congress

    A heterozygous splicing variant in NPC2 in a patient with PSP

    C. Castro-Fernández, C. García-Sancho, V. Rodríguez-Sureda, R. Martínez-Regueiro, P. Aguiar, P. Blanco-Arias, C. Pérez-Sousa, P. Díaz, C. Domínguez, M. Fernández-Prieto, T. García-Sobrino, J. Cortés, M. Arias, M.J. Sobrido (Santiago de Compostela, Spain)

    Objective: Clinical, neuroimaging, genetic and biochemical characterization of a patient with a PSP-like phenotype carrying a splicing mutation in NPC2. Background: Niemann-Pick type C disease…
  • 2016 International Congress

    Density of metabotropic glutamate receptors subtype 1 in de novo patients with Parkinson’s disease using 11C-ITMM PET

    M. Mishina, M. Suzuki, K. Ishii, M. Sakata, K. Wagetsuma, K. Ishibashi, J. Toyohara, M.R. Zhang, K. Kimura, K. Ishiwata (Kawasaki, Japan)

    Objective: To investigate the mapping of metabotropic glutamate receptor subtype 1 (mGluR1) in elderly normal and de novo patients with Parkinson's disease (PD) using N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-4-11C…
  • 2016 International Congress

    Multimodal imaging assessment of nigrostriatal pathway in Parkinson’s disease using 11C-PE2I PET and neuromelanin-sensitive MR

    A. Martin-Bastida, N.P. Lao-Kaim, A.A. Roussakis, W. Li, M. Politis, N. Valle-Guzman, Z. Kefalopoulou, G. Paul, H. Widner, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

    Objective: To evaluate the nigrostratal pathway with multimodal assessment using striatal 11C-PE2I PET and nigral Neuromelanin-sensitive MR in Parkinson's disease. Background: The main pathological features…
  • 2016 International Congress

    Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [18F]MNI-659 PET imaging

    D.S. Russell, D.L. Jennings, O. Barret, G.D. Tamagnan, D. Alagille, J.P. Seibyl, K.L. Marek (New Haven, CT, USA)

    Objective: To evaluate the feasibility of [18F]MNI-659 PET, a striatal PDE10A imaging tracer, as a imaging biomarker in PD. Background: PDE10 is highly and specifically…
  • 2016 International Congress

    Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease

    W. Li, N.P. Lao-Kaim, A.A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R.A. Barker, P. Piccini (London, United Kingdom)

    Objective: The aims of this study were to quantify striatal uptake of 18F-DOPA and 11C-PE2I in the same group of PD patients, to assess the…
  • 2016 International Congress

    Persistent drug-induced parkinsonism with normal dopamine transporter imaging

    J.W. Lee, J.Y. Hong, J.S. Oh, I. Lee, J.S. Kim, Y.H. Sohn, P.H. Lee (Wonju, Korea)

    Objective: We investigated whether patients with persistent drug-induced parkinsonism (DIP) showing visually normal dopamine transporter (DAT) imaging had minimal changes in striatal DAT activity using…
  • 2016 International Congress

    Cerebellar GABA-A receptor activity is inversely correlated with gait speed in Parkinson’s disease

    N.I. Bohnen, K.A. Frey, R.A. Koeppe, P.J.H. Scott, M.L.T.M. Muller (Ann Arbor, MI, USA)

    Objective: To investigate the relationship between regional cerebral expression of benzodiazepine receptors and gait speed in Parkinson's disease (PD). Background: Flumazenil is a short-acting intravenously…
  • 2016 International Congress

    Frontal dysfunction in Tourette syndrome: A PET-FDG study

    R. García-Ramos, N. Gonzalez, E. Lopez Valdes, F. Alonso, N. Cabrera, I. Parees, M.J. Catalán, J. Matías-Guíu Antem (Madrid, Spain)

    Objective: Our objective was study the metabolism of brain in a group of patients with Tourette´s Syndrome. Background: The pathophysiology and anatomical basis of Tourette…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley